Skip to main navigation Skip to search Skip to main content

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

  • Ranjana H. Advani
  • , Pauline Brice
  • , Nancy L. Bartlett
  • , Joseph D. Rosenblatt
  • , Tim Illidge
  • , Jeffrey Matous
  • , Radhakrishnan Ramchandren
  • , Michelle A. Fanale
  • , Joseph M. Connors
  • , Yin Yang
  • , Dirk Huebner
  • , Dana A. Kennedy
  • , Andrei R. Shustov
  • Stanford University
  • Hematology, Hopital Saint Louis, Paris, France,
  • Washington University in St. Louis
  • University of Miami
  • Christie Hospital NHS, Manchester, United Kingdom,
  • Colorado Blood Cancer Institute, Denver, CO, USA,
  • Wayne State University
  • University of Texas MD Anderson Cancer Center
  • BC Cancer Agency
  • Seattle Genetics
  • Millennium Pharmaceuticals
  • University of Washington

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume122
Issue number21
DOIs
StatePublished - Nov 15 2013
Externally publishedYes

Disciplines

  • Immunology and Infectious Disease
  • Medicine and Health Sciences
  • Internal Medicine

Cite this